Home

ナノキャリア（4571）

1.
2.
3. DDS
4. TOKAI
5. MediCelleQ 2005 3 Debiopharm S A NC 4016 2009 3 Debiopharm 1 2011 3
6. CEO 1996 6 1997 8 1 4403 2001 1
7. sShared 6Qesearch http www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved e 4571 SR Research Report 2013 12 26 2013 3 2013 5 13 2013 3 Orient Europharma Co Ltd 373 7 99
8. 2013 6 19 siRNA 3 1mg kg siRNA
9. 100nm EPR Enhanced Permeation and Retention Effect sSh
10. 1 II III IV 1 TI 1 11 II es Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 84 87 4571 SR Research Report 2013 12 26
11. DACHPt 1 1
12. 19 5 4571 SR Research Report 2013 12 26
13. NC 6004 2006 5 1 Orient Europharma Co Ltd OEP NC 6004
14. Debiopharm 2011 5 12 17 LFB Biotechnologies LFB rhFVIIa recombinant human factor VIla VII NC 4026 2011 3 LFB 2011 7 20
15. siRNA 3 2013 5 13 Regulus Therapeutics Inc RNA sShared 6Qesearch http www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
16. Medicelle 2009 11 NK105 NK105 6 2012 10
17. PEG sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
18. 3 000nm 300nm 100nm 100nm
19. ATP Adenosine Triphosphate 3 WW C 10 20nm 2011 8 RNAi 2013 5 Regulus Therapeutics Inc microRNA RNA
20. NC 6004 NC 4016 2013 3 335 1 130 2013 3 2013 3 1 4 Shared 6Qesearch http 7 www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved 64 87 we s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 2 2013 2 18 NC 6004
21. 2013 10 2013 9 sShared 6Qesearch http www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved
22. TV Oo 0 FDA FDA 2006 0 IND Investigational New Drug
23. Novosom pH CD40 Calando Pharma IT 101 Calando Cyclocert TM Calando PEG Calando siRNA Access Pharmaceuticals Tnc
24. 2 s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
25. 180nm 1800nm 4000nm 7300nm 8000nm CK 20 100 nm a Shared esearch http Www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
26. 1 4523 LFB Biotechnologies siRNA 2012 3 2012 5 10 2012 3 346 310 7 334 2011 3 520 366 2011 3 550 398 2011 3 555
27. 2 a T Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 80 87 es s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
28. siRNA siRNA NanoFect 2013 6 siRNA siRNA 3 2013 6 NanoFect
29. 21 a 12 i lt CNK105 10 8 IT TLO 23 NC 6004 9 2
30. 4 Shared 6Qesearch http 7 www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved 46 87 we 4571 SR Research Report 2013 12 26 NC 6004 NC 4016 NC 6004 III 2012 3
31. NC 6004 2 760 NC 4016 II 912
32. 1 4502 2012 4 siRNA 2013 3 36 41 2 sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 10 Must 7 37 PE1 6 58 5 56 3 44 3 38
33. 12 000 24 000 NK105 1 4272 2012 7 III NC 6004 Orient Europharma Co Ltd II 2013
34. 1 nm 10 1 DDS Drug Delivery System 20 100
35. SR Inc SR Tnc Shared Researcnh SR Inc SR Inc SR Inc SR Tnc
36. 3 NanoFect 2013 5 2013 5 31 200980118842 4
37. NK105 AUC NK105 2010 8 1 2012 7 III II NK105 380 2 2012 7
38. OEP 2014 1 IND Phase 2013 12 24 2014 3 2 2014 3 2 2013 12 17
39. DDS 2012 3 2012 3
40. NanoBiotix X NanoBiotix 4571 SR Research Report 2013 12 26
41. OEP 2 a ER 2014 3 2013 9 17 OEP OP Nano NC 6004 Orient Europharma Co Ltd OEP OEP OP Nano 1 NT
42. PE1 2011 4 3 220 31 19 15 596 11 5 Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved e 4571 SR Research Report 2013 12 26
43. 12 000 12 000 24 000 2013 3 NK105 1 4272 2012 7 III
44. 2013 5 1 IND PMDA 1 4523 2013 3 3 2013 2 12 2013 3 3 2013 3 3 Orient Europharma Co Ltd 201
45. DDS oO 4571 SR Research Report 2013 12 26 2011 ea di 46 6 2 393 4 3 794 37 196 1 6 268 15 2011 9 Eloxatin Sanofi 14
46. OEP I 2013 6 PI b T NC 4016 2013 5 1 MD Anderson NC 6300 2013 5 1 9 ADCM Antibody Drug Conju
47. RNA microRNA microRNA 20 AInylam Pharmaceuticals Isis Pharmaceuticals C microRNA microRNA siRNA
48. MD II 2 2013 6 20 1 4063 s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
49. sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 3 1 4403 63 579 30 7 43 303 20 9 37 436 18 09 23 250 11 2 13 379 6 4 TLO JST JST
50. SR Inc SR Tnc SR tnc http www sharedresearch jp Email info sharedresearch jp 3 31 12 03 5834 8787 Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights
51. 2012 3 2013 3 2007 3 2013 3 e gt SadQeweami http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved Shared csearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
52. 1978 FDA DNA Bristol Myers Squibb EL Shared 6Qesearch http 7 www sharedresearchjp Copyright C 2013 Shared Research Inc All
53. 2012 10 1 2013 II NC 4016 I MD The University of Texas MD Anderson Cancer Cente NC 6300 2013 1
54. 2012 10 9 DDS 2012 10 5 NC 6004 1 NC 6004 IND Investigational New Drug 2012 6 27 NC 6004 1 NC 6004 10 2 4571 SR Research Report 2013 12 26 NC 6004 II III
55. 1980 2005 7 CSO Chief Scientific Officer 22 CFO Chief Financial Officer 2011 6 1976 1999 4 MG CFO 2003 9 2008 1 C 4571 SR Research Report 2013 12 26
56. NK105 2002 6 1 2004 5 2006 4 Drug Delivery System 24 1 2009 NK105 AUC 15 NK105 150mg sq m 210mg sq m 4 1 2007 11 II II
57. 2013 3 2013 2 99 89 267 509 267 510 268 511 2013 2 370 267 812 1 147 828 1 164 831 1 167 Shared 6Qesearch http 7 www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved 68 87 we 4571 SR Research Report 2013 12 26 2012 9 2012 9 21 NC 6004 Phase 1 II Phase I stage Orient Europharma NC 6004 Phas
58. 3 A 3 120 140nm B 30 50nm siRNA ATP s Shared Besearch http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared Besearch http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
59. OEP I II 2013 6 NC 6004 I II TFDA Taiwan Food and Drug Administration 1 II Hydration
60. ADCM Antibody Drug Conjugated Micelle s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 AD
61. DDS GMP Good Manufacturing Practice International Conference on Harmonization ICH Abraxis Bioscience Inc DDS 82 87 4571 SR Research Report 2013 12 26 In Vitro
62. 4 3 pH 8 pH 17 5 14 ER EPS PCT SR Re Shared esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved Shared
63. 800 OEP OEP OEP OEP 2013 9 OP Nano OP Nano 29 5 2016 12 sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 1 2 SR 2012 8 31
64. 2009 3 Orient Europharma 2011 3 2012 3 2013 3 2013 3 7 700 1 2 37 128 8 19 000 56 128 63 828 2013 3
65. PFS Progression Free Survival s Shared 6Qesearch la http www sharedresearch jp Copyright C 2013 Shared Research Inc Al Rights Reserved 85 87 e lt Shared esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved w 4571 SR Research Report 2013 12 26 03 3548 0213 1996 6 14 HP http www nanocarrierCO D TIR IR info nanocarrier co jp CEO CBO CSO CFO 3 2013 6 36 41 2 4 407 2013 3 277 0882
66. 1 2010 2011 II NC 6004 Orient Europharma Co Ltd 1 II MTD NC 6004 sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 NC 4016 Debiopharm 2011 3
67. 2011 3 2012 3 2011 3 1 391 4571 SR Research Report 2013 12 26 09 3 10 3 11 3 12 3 13 3 14 3 354 118 84 346 374 297 34 6 66 7 28 4 310 7 7 9 20 5 247 71 51 125 273 106 47 33 221 101 30 1 39 8 39 4 63 9 27 0 638 540 553 555 628 180 4 458 0 655 9 160 2 167 9 532 493 520 334 527 1 238 9 4 1 2 106 1 4 31 35 12 524 492 550 366 432 1 240 2 0 0 0 0 0 5 0 0 550 31 0 50 4
68. TFDA Taiwan Food and Drug Administration IDB Industrial Development Bureau Ministry of Economic Affairs NC 6004 NC 4016 NC 4016
69. J P Morgan Securities plc P 5 460 6 300 JP P Morgan Securities plc 2013 11 22 2013 11 25 sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved Shared 6Qes
70. TLO 1 TLO 7 10 SIRNA 7 ER SE De _ 78 SE
71. Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 OP Nano OP Nano gt NT 1 000 2016 12 8 900m2 lt Huwei Yunlin OP Nano 2015 3 NC 6004 2013 6 2013 9 10 2014 3 2014 3
72. NK105 Medius Associates 2001 0 5 I 5 10 II 8 15 III 10 20 20 s Shared 6Qesearch http www sharedresearch jp Copyright
73. 1 IL 2 2 IL 2 CTL IL 2 IL 2 2012 10 2012 10 26 1 4063 1 57 473 2012 4 26 2012 10 25 13 599 12 000 s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12
74. 1 10 1 1 1 000 000 000 1 100 Pt DNA q PEG
75. 526 2012 3 333 432 366 484 398 Orient Europharma Co Ltd 242 NC 6004 1 1 035 237 2012 11 Orient Europharma Co Ltd NC 6004
76. RNAi siRNA RNA RNAi PTGS SiRNA RNA RNA RNA RNA RNA siRNA 1999 Science RNA mRNA 1 RNA mRNA RNA mmRNA RNA RNA RNAi s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 RNA 20 RNA tRNA RNA
77. Genentech Roche
78. 2012 3 2 876 2010 3 1 006 2011 3 1 767 2011 3 2012 3 2012 3 http Www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2007 3 2011 3 2012 3 1 700 2008 3 IPO
79. RNA RNA 2013 5 9 NC 6300 K 912 pH NC 6300 K 912 2013 5 7 NC 6300 K 912 IND 1 NC 6300 K 912
80. 700 J P Morgan Securities plc 6 300 840 5 460 JP P Morgan Securities plc P 840
81. Shared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 69787 4571 SR Research Report 2013 12 26 2012 7 2012 7 30 2013 3 89 69 509 529 510 530 511 531 267 242 1 147 1 172 1 164 1 189 1 167 1 192 2012 7 17 1 NK105
82. 2008 9 Orient Europharma Co Ltd NC 6004 Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved e 4571 SR Research Report 2013 12 26 2008 12 NC 6004 1 II 2008 12 Debiopharm S A NC 4016 2009 5 TLO 2009 11 2009 12 TLO 2010 8 NK105
83. 2013 2 13 NC 6004 2013 2 7 NC 6004 2013 1 2013 1 16 NC 4016 2012 11 2012 11 9 LFB Biotechnologies LFB Biotechnologies LFB 2010 10 LFB VII
84. 2013 12 5 e 1 sShared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 529476 NanoFect 1 B B 30 5
85. DDS QOL DDS C 60 Shared Gewearch http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 DDS Johnson amp Johnson Abraxis BioScience Nasdaq ABII
86. 1 4272 III 2012 7 10 pH 2012 7 2 DDS 2012 6 2012 6 27 NC 6004 IND NC 6004 IND Investigational New Drug 6 27 IND 1 sShared 6Qesearch http www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
87. III IIb III 2012 6 PMDA I 2012 10 1 sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved e 4571 SR Research Report 2013 12 26 NC 4016 1 II 2013 1 IIa MD The University of Texas MD Anderson Cancer Cente
88. 1 RNA 20 25 1 RNA 2 siRNA mRNA RNA 500 RNA 3 1 RNA microRNA RNA 4571 SR Research Report 2013 12 26
89. 2013 5 NC 6004 2 3 3 1 2 4571 SR Research Report 2013 12 26
90. 432 2012 3 19 NC 6004 2 760 2012 4 2016 3 NC 4016 912 2012 4 2016 3 NC 6004 NC 4016
91. 99 52 7 267 109 267 110 268 111 NK105 1 4272 2012 7 III NC 6004 Orient Europharma Co Ltd II 2012 II
92. Hydration NC 6004 NC 6004 7 NC 6004 OEP s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 11 NC 6004 300
93. III IIb III 2012 6 5 NC 6004 II Orient Europharma 1 NC 6004 II II III IND NC 6004
94. In Vivo 1976 Debiopharm Debiopharm 1994 Sanofi Aventis 1999 2004 Sanofi Aventis Eloxatin 2007 2013 2016
95. 1 268 900 1 268 900 1 257 460 2013 10 11 2013 10 7 1 4063 2013 10 7 33 600
96. 501 267 71 436 267 437 268 NK105 1 4272 2012 7 III NC 6004 gt SadQeweami http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 OEP 2013 6
97. Nanocap 5 a mm ManoCap Medicelle 2 Medicelle Active Delivery ystem NanoCoat AL siRNA siRNA small interfering RNA RNA mRNA RNA RNA siRNA siRNA sShared eSsearch http Www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4
98. pH7 pH pH7 pH7 pH7 35 pH RNA DNA DNA 2 RNA 1 RNA mRNA RNA DNA RNA RNA RNAi
99. NK105 SR 30 14 2 2 59 28 SR NC 6004 NC 6004 4571 SR Research Report 2013 12 26 QOL Quality of Life
100. 1 2 SR ADCM
101. 2013 11 14 s Shared Research http Www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved w 4571 SR Research Report 2013 12 26 2009250393 2013 11 11 2014 3 2 2013 10 21 2013 10 7 1 268 900
102. DNA DNA NC 6300 pH pH NC 6300 Improved anti tumor activity of stabilized anthracycline polymeric micelle formulation NC 630
103. 2013 3 371 370 488 812 406 828 461 831 NC 4016 NC 6004 I II 2013 3 335 85 35 15 2014 3 297 1 238 1 240 1 262 2013 3
104. Debiopharm 1 2012 3 Debiopharm s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 NC 4016 48 28 8mg m 2011 3 11 Debiopharm I MD 2013 11 2018 NC 6300
105. 19 800 2016 Orient Europharma Co Ltd 2012 11 OEP 1 2 OEP NC 6004 API OEP NC 6004 OEP OEP OEP
106. 3 2012 10 Orient Europharma Co Ltd NC 6004 2013 5 NC 6300 K 912 1 2013 5 NC 4016 1 2013 6 NC 6004 Ib I 2013 6 Orient Europharma Co Ltd NC 6004 amp 2013 9 2013 9 30 2012 7
107. 2 67 Cyntec Co Ltd OEP 2 53 2 29 MSIP CLIENT SECURITIES 1 20 0 94 SR 2013 3 2013 3 IR 103 0027 3 2 2 03 3548 0217 SR Research Report 2013 12 26 gt SadQeweami http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved lt Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved lt 4571 SR Research Report 2013 12 26 DNA DNA pH
108. NC 6300 2013 1 2013 3 1 2012 8 7 2013 3 1 2012 7 30 2013 3 10 179 2012 3 1 154 179 2012 3 1 154 180 2012 3 1 155 NK105 1 427
109. 1 5 7 PDMA 2013 4 2013 4 4 NC 4016 2013 3 21 NC 4016 2013 3 2013 3 21 NC 4016 s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 3 19 2013 3 2014 3
110. 416 297 1 174 1 238 1 176 1 240 1 198 1 262 1 NC 6004 Orient Europharma Co Ltd 1 II Orient Europharma 2 10 4571 SR Research Repor
111. sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 24 7 NC 6004 Orient Europharma Co Ltd OEP 2013 6 1 2013 6 P I b II 3 3 NC 4016 201
112. 2012 3 21 30 28 29 988 840 28 000 PE1 780 60 2 2012 3 21 20 43 30 702 860 28 000 PE1 800 60 8 2012 3 21 15 67 67 000 2 025 15 2 010
113. Pt 17 2 11 8 9 52 9 64 79 12 3 5 1 NC 6004 Phase II stage NC 6004 PhaseI IND Investigational New Drug 6
114. IIb III 1 III IIb III 2012 10 1 NC 6004 2013 3 NC 6004 Orient Europharma Co Ltd 1 2 Orient Europharma 1 2 3
115. 430 516 NC 4016 NC 6004 2012 1 2012 3 2012 2 9 2012 3 3 2012 1 2012 1 26 4571 SR Research Report 2013 12 26 1 2 8 1
116. 1 3 15 PEG
117. rRNA RNA 300 20 10 300 DNA RNA DNA RNA
118. 269 29 28 27 26 http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2008 3 Debiopharm 148 56 NK105 101 38 2009 3 Debiopharm 229 659 Orient Europharma 119 33 6 2010 3 2010 3 26 2010 3 2010 3 Debiopharm 55 479 14 11 28 2
119. 2009 10 2 IL 2 IL 2 IL 2 T CTL
120. II 201 1 7 II 5 1 22 2012 5 2012 5 10 2012 4 2012 4 26 DDS 2012 4 17 sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared Research http
121. s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 1 4502 100 amp 2003 90 1 458 2010 amp 80 2010
122. 2006 5 NC 6004 1 2006 6 NC 4010 2006 7 TLO 2007 2 TLO pH 2007 10 Debiopharm S A NC 4016 2007 11 NK105 II 2008 3 2008 4 TLO
123. NK105 siRNA ee e Medicel NC 6004 2 NC 4016 NC 6300 _ vv Nanocoar gt WMA 4 Active Targeting 2013 3 31 Shared esearch http Www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 Nano Carrier 2013 3 31 SR Research Report 2013 12 26
124. II NC 6300 2011 9 2013 1 siRNA siRNA
125. 2011 9 NC 6300 2012 3 1 4523 2012 3 1 700 2 025
126. s Shared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 09 3 10 3 11 3 12 3 13 3 1 369 1 006 1 872 2 981 5 050 43 6 6 1 5 11 22 60 99 181 26 31 43 31 237 1 450 1 066 1 981 3 112 5 473 29 24 19 38 19 38 35 27 2 0 12 11 11 510 114 80 70 57 550 133 1 529 1 135 2 038 3 663 5 606 9 11 2 5 50 0 0 0 0 0 63 110 188 99 99 71 121 189 104 149 0 0 0 1 700 1 040 0 0 0 104 16 0 0 0 1 804 1 056 71 121 189 1 804 1 205 1 458 1 012 1 848 1 829 4 353 0 3 1 30 48 1 458 1 014 1 849 1 859 4 401 1 529 1 135 2 038 3 663 5 606 46 17 65 95 136 0 0 0 1 700 1 040 1 369 1 006 1 872 1 281 4 010 SR
127. 30 000 PE1 62 5 1 2 8 297 988 30 702 67 000 127 690 2012 1 25 234 885 54 49 sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved es s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 25
128. 5 4 19 047 169 6550 2008 3 5 3 IR http www nanocarriercO D ir index html IR 03 3548 0217 325 5 081 2013 3 2013 3 4571 SR Research Report 2013 12 26 SR GCA
129. 2018 3 SR NC 6004 NC 4016 2012 NC 6004 NC 4016 II 4571 SR Research Report 2013 12 26 NC 6004 IND Phase Il Phase llb Ill Phase Ilby phasei Phase Ilb Phase Ilb Phase IIl IND Phase Eu 2008 3 2014 3
130. 9 TLO 24 6 NC 4016 3 8 TLO Sa 2 8 11
131. NC 4016 DACH Prolindac 2010 II HPMA Supratek Pharma DDS SP1049C 2005 II
132. SR 2006 3 2013 3 2013 3 2006 3 2013 3 2012 3 2006 3 300 499 2007 3 2008 3 3 IPO 2011 3
133. 325 307 16 49 1 09 3 10 3 11 3 12 3 13 3 127 129 221 235 325 EPS 4 195 3 875 3 600 1 742 1 885 EPS DPS 0 0 0 0 0 BPS 11 475 7 868 8 364 7 783 13 529 SR IPO 10 1 http 7www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 09 3 10 3 11 3 12 3 13 3 CF A 457 452 578 293 635 CF B 4 8 5 1 721 121 FCF A B 461 460 582 2 015 757 CF 75 97 1 449 1 924 2 327 A 16 16 16 18 7 B 3 2 4 19 20 C 71 29 48 30 41 FCF A B C 440 452 590 429 538
134. 40 87 4571 SR Research Report 2013 12 26 NC 6004 Orient Europharma Co Ltd II 2013 2012 10 1 2013 NC 4016 I MD The University of Texas MD Anderson Cancer Cente NC 6300
135. sShared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2012 NATURE Vol491 S58 60 22 November 2012 OUTLOOK PHYSIAL SCIENTISTS TAKE ON CANCER 2013 3 2 2012 11 9 2013 3 2 2013 3 2
136. 5 600 28 000 4571 SR Research Report 2013 12 26 2013 10 21 2013 10 23 0 90 1 00 P J P Morgan Securities plc 2013 10 28 2013 10 30 8 400 P E 1 7 700
137. 8 NK105 NanoCap NK105 esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 1 4272
138. 29 500 000 NC 6004 OEP 2012 11 OP Nano OEP NC 6004 NC 6004 OP Nano OP Nano GMP Good Manufacturing Practice
139. 4571 SR Research Report 2013 12 26 2013 3 2011 a 207 NK105 561 YA 2 gt 4 Sa 43 se Sa 115 eee me fr mm te 165 IND NC 4016 IND Eowtn NC 6300 206 IND Ellence 692 Coal 2013 NK105 NC 6004 NC 4016 NC 2 4 4
140. NK105 1 4272 2012 III NC 6004 Orient Europharma Co Ltd 1 es sShared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 II 2011 7 II NC 4016 1
141. 5 1 361 284 355 289 356 289 2012 11 Orient Europharma Co Ltd es sShared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 NC 6004 1 4063 12 000
142. 2 MediCelle 3 NanoCoat SadQeweami http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 BN NanoCap
143. TLO 2002 6 1 4272 Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved e 4571 SR Research Report 2013 12 26 2002 11 NC 4010 2004 5 NK105 1 2004 5 TLO 2005 3 Debiopharm S A NC 4016
144. 2 4 1 2011 9 290 2011 3 2011 5 12 2011 3 NK105 1 4272 II III 2011 2 21 III 2015
145. 2012 10 1 10 2 2012 10 2013 2013 11 OEP NC 6004
146. 2006 9 2 700 37 09 29 6 18 5 2012 1 11 1996 6 CEO iPS CBO Chief Business Development Officer 2008 6 2007 12 2008 5 MG
147. gt NC 6004 NC 4016 2013 5 NC 6004 2017 3 2018 3 800 1 100 8 Shar ed esearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26
148. 4571 SR Research Report 2013 12 26 2008 525801 2013 5 30 NC 4016 IND NC 4016 1 5 29 FDA Food and Drug Administration 1 MD Phase I Unit II 1 2013 5 20 1 4403
149. 1 2010 10 LFB Biotechnologies rhFVIIa VI 2011 3 Debiopharm S A LICENSE AND SUPPLY AGREEMENT Termination Agreement 2011 7 LFB 2011 7 NC 6004 II 2011 8 2011 9 NC 6300 2012 3 2012 3 1 4523 2012 7 4571 SR Research Report 2013 12 26 2012 10 NC 6004 1
150. 522 492 553 396 482 2 2 2 2 2 524 495 555 398 484 1 262 a SR 55 2003 3 96 141 2004 3 123 1 2503 2005 3 Debiopharm 113 2006 3 Debiopharm 1 4523 108 NC 6004 1 2007 3 Debiopharm 27
151. A 54 54 ER Ra RE 57 i i NN 75 76 2 77 77 77 78 78 I ES 86 Shar ed 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 09 3 10 3 11 3 12 3 13 3 14 3 354 118 84 346 374 416 34 6 66 7 28 4 310 7 7 9 11 3 106 47 33 221 101 45 3 55 9 29 2 566 4 54 4 30 1 39 8 39 4 63 9 27 0 532 493 520 334 527 1 174 3 524 492 550 366 432 1 176 524 495 555 398 484 1 198 127 129 221 235 325 EPS 4 194 6 3 874 6 3 599 9 1 741 8 1 885 4 3 515 2 DPS 0 0 0 0 0 0 0 0 0 0 0 0 BPS 11 475 1 7 868 4 8 364 3 7 783 2 13 528 8 1 369 1 006 1 872 2 981 5 050 43 6 6 1 5 11 22 60 99 181 1 450 1 066 1 981 3 112 5 473 1 529 1 135 2 038 3 663 5 606 9 11 2 5
152. 2013 3 1 238 2013 3 526 1 240 2013 3 432 1 262 2013 3 484 2014 3 2012 NC 6004 NC 4016
153. 2013 9 25 es sShared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 9 24 NC 6004 NC 6004 Orient Europharma Co Ltd OEP
154. III IIb III 4571 SR Research Report 2013 12 26 2012 6 PMDA 1 III IIb III NC 4016 1 II NC 6300 2013 1
155. Shared search SR Research Report 2013 12 26 4571 sr_inquiries Gsharedresearch jp 4571 SR Research Report 2013 12 26 RY 4 4 4 9 A Ai 15 15 RY 34 39 oa 40 49 51 3 53 2 2y
156. Shared Gewearch http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 SC Po CMO CRO 1 2 3 3 1 3
157. Shared Gewearch http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 NC 6004 Orient Europharma Co Ltd 1 II 2013 2013 2012 10 I NC 401
158. 127 7 167 9 222 4 267 260 527 501 673 1 174 267 165 432 436 740 1 176 268 216 484 437 761 1 198 3 SR 2013 9 10 2014 3 Orient Europharma Co Ltd 297 20 59 2013 5 1 144 2013 3 510 391
159. 26 689 676 2012 11 15 5 089 2012 10 26 236 395 9 229
160. C 2013 Shared Research Inc All Rights Reserved lt Shared Wesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved e 4571 SR Research Report 2013 12 26 SW Strengths Weaknesses 30 2013 11
161. DDS 2005 AstraZeneca 2009 3 1 500 2008 3 3 600 NK105 SR DDS AstraZeneca Teva EGFR Roche Genentech Roche HER2 neu
162. M Harada I Bobe H Saito N Shibata R Tanaka T Hayashi Y Kato Cancer Science 102 1 192 199 2011 2011 9 NC 6300 NC 6300 24 s Shared Research http Wwww share
163. Reserved
164. Rights Reserved 83 87 we 4571 SR Research Report 2013 12 26 Dach 1967 Bristol Myers Squibb
165. 0nm siRNA ATP 2 2013 11 22 NC 6004 NC 6004 2010 517837 2013 11 18 NC 6004 NC 6004 098118350
166. 2 2012 7 III NK105 380 2 2012 7 NC 6004 Orient Europharma Co Ltd II 2012 II
167. 2018 10 NC 6004 NC 4016 siRNA ADCM Antibody Drug Conjugated Micelle 3 amp 4571 SR Research Report 2013 12 26 13 3 14 3 14 3 EzjgD 1Q 2Q 3Q te 1Q 2Q 3Q 4Q 10 90 102 173 150 176 78 3 416 120 1 565 60644 283 14302 964 11 3 30 40 62 28 98 125 79 1 656 2099 45 2 61 4 16 1 65 2
168. 3 5 I MD Anderson NC 6300 2013 5 1 sShared 6Qesearch http www sharedresearchjp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2014 3 14 3 13 3 14 3 99 274 374 326 90 416 52 7 101 4 7 9 228 0 67 1 11 3 89 184 273 102 11 90 101 223 94 3 166 7 54 4 1976 9 10 8 32 9 27 0 68 5 277 350 628 724 279 2
169. 50 0 0 0 1 700 1 040 71 121 189 1 804 1 205 1 458 1 012 1 848 1 829 4 353 1 369 1 006 1 872 1 281 4 010 46 17 65 95 136 457 452 578 293 635 4 8 5 1 721 121 75 97 1 449 1 924 2 327 ROA 29 4 37 1 35 0 14 0 10 5 ROE 31 2 40 1 38 8 21 7 15 7 95 4 89 4 90 7 50 7 78 5 SR Shared 5Mesearch http Www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 12 26 NC 6004 Orient Europharma Co Ltd OEP NC 6004
170. 571 SR Research Report 2013 12 26 AMD siRNA siRNA sIiRNA 2010 9 2009 5 25 TIO
171. 6 1 MD 1 2013 1 IND NC 6300 1 IND 5 PMDA 2013 10
172. 71 4 149 128 157 194 375 349 09 13 5 21 7 49 0 1518 1722 1520 7 143 3 154 1 112 1 250 2 198 7 179 88 94 166 277 224 1 174 179 87 88 77 190 246 1 176 180 88 88 128 191 246 1 198 SR 2014 3 2 2013 11 11 2014 3 2 2014 3 2 Orient Europharma Co Ltd OEP 326 228 0
173. 82 10 Lupron Enantone AbbVie 1478 11 Xeloda Roche 1219 15 Zoladex AstraZeneca 943 2013 2000 16 Sanofi Aventis 2008 20 2010 2003 DDS 1990 DDS DDS
174. CM 1 1 2011 10 1 W 2010 10 1 2012 7
175. VII VII VII VII LFB s Shared Research http Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2370
176. Wwww sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2012 4 4 2012 3 2012 3 29 2 2012 2 2012 2 28 2012 3 340 440 360 512 390 514
177. ared 6Qesearch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 EPR Enhanced permeability and retsntion effect J Y Miatsumura et al Comcer Research 1986 46 6387 1 NanoCap 2 Medicelle 3 NanoCoat 3 NanoCap
178. dresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 5 NC 6300 K 912 IND 2013 9 1 siRNA 2013 5 sRNA
179. e I stage 71 Dr Wu Chou Su National Cheng Kung University Hospital Taiwan PhaseI GEM NC 6004 MTD Maximum tolerated dose RD Recommended dose 19 NC 6004 3 1 30 60 90 120 mg mi GEM 3 2 1000 mg m 1 8 Dr Wu Chou Su Phase I stage NC 6004 MTD 120 mg m RD 90 mg m
180. earch http www sharedresearch jp Copyright C 2013 Shared Research Inc All Rights Reserved 4571 SR Research Report 2013 12 26 2013 9 30 364 352 33 600 397 952 6 300 404 252 JP PMorgan L Securities plc 11 216 8 916 2013 11 2018 10 2 300 2013 11
181. gated Micelle siRNA 2014 3 1 2013 8 9 2014 3 1 150 2013 3 1 10 277 179 190 179 191 180 NK105
182. t 2013 12 26 2013 6 2013 6 25 NC 6004 NC 6004 Orient Europharma Co Ltd OEP NC 6004 1 II O E P 6 24 TFDA Taiwan Food and Drug Administration 2013 6 24 NC 6004 IND NC 6004 6 21 FDA Food and Drug Administration

ナノキャリア（4571）

Contents

Download Pdf Manuals

Related Search

Related Contents